Templeton questions AsiaPharmÆs financial results
Templeton, a minority shareholder of AsiaPharm, is opposing a S$357.4 million management buyout offer for the Chinese pharmaceutical company and says the latest fourth quarter results are crucial in assessing the offer.
Templeton Asset Management, the Singapore-based Asian entity of US asset management firm Franklin Templeton Investments, is questioning AsiaPharm GroupÆs 2007 financial results that were released in late-February and is seeking a more detailed explanation. Templeton is a minority shareholder in AsiaPharm and is opposing a S$357.4 million ($259 million) management buyout offer made in early-February for the Chinese pharmaceutical company. It opposes on the grounds that it believes the …
Sign In to Your Account
Access Exclusive AsianInvestor Content!
Please sign in to your subscription to unlock full access to our premium AI resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial—no registration fees required. Click the link to get started.
Note: This free trial is a one-time offer.
¬ Haymarket Media Limited. All rights reserved.